



Cite this: *New J. Chem.*, 2017, 41, 1566

# Synthesis and evaluation of benzothiazole-triazole and benzothiadiazole-triazole scaffolds as potential molecular probes for amyloid- $\beta$ aggregation†

Christine Dyrager,<sup>‡\*ab</sup> Rafael Pinto Vieira,<sup>acd</sup> Sofie Nyström,<sup>b</sup> K. Peter R. Nilsson<sup>b</sup> and Tim Storr<sup>a</sup>

Small-molecule ligands that bind to misfolded protein aggregates are essential tools for the study and detection of pathological hallmarks in neurodegenerative disorders, such as Alzheimer's disease (AD). In the present study, three compounds (one benzothiazole-triazole, **L1**, and two benzothiadiazole-triazoles, **L2** and **L3**) were synthesized via a modular approach (azide-alkyne cycloaddition) and evaluated as potential ligands for amyloid- $\beta$  (A $\beta$ ) aggregates. The binding to amyloid-like fibrils, generated from recombinant A $\beta$ <sub>1–42</sub>, were studied and the binding specificity to amyloid deposits was evaluated in brain sections from transgenic mice with AD pathology. All three derivatives showed significant reduced emission in the presence of recombinant A $\beta$ <sub>1–42</sub> amyloid fibrils. In addition, the observed binding to A $\beta$  deposits in tissue sections suggests that the benzothiazole-triazole and benzothiadiazole-triazole structures are promising molecular scaffolds that can be modified for binding to specific protein aggregates.

Received 31st May 2016,  
Accepted 5th January 2017

DOI: 10.1039/c6nj01703g

www.rsc.org/njc

## 1. Introduction

One of the common pathological hallmarks of neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's and Huntington's disease, and the infectious prion diseases are the formation of misfolded protein aggregates in the brain.<sup>1–4</sup> Thus, development of new molecular probes for the detection of protein aggregates is of great importance in order to understand the pathology of these diseases.<sup>5–8</sup> For example, probes that can be prepared via a modular synthetic approach to generate structures with diversity are desirable. To date, the most commonly used ligands for studying protein aggregation are thioflavin T (ThT) and Congo red (CR) (Fig. 1). ThT, which is a benzothiazole dye, is used due to its impressive increase in fluorescence intensity (ca. 1000-fold) in the presence of protein fibrils, a phenomenon that is due to conformational rigidity

upon binding.<sup>9–11</sup> However, the practical use of ThT has been debated since it has limitations; e.g. it is not able to distinguish between prefibrillar and fibrillar aggregates and some protein aggregates do not affect its fluorescence, leading to false negatives.<sup>12,13</sup> In addition, CR, (an aromatic azo dye) is commonly used for staining protein aggregates in histology samples.<sup>14–16</sup> However, CR staining can give misleading results due to the thickness of the sample and the orientation of the amyloid deposits.<sup>13</sup> Hence, CR staining usually requires experience and sample control in order to generate reliable results.<sup>17</sup> Although both ThT and CR are useful and well-established dyes for amyloid detection in tissue there is a need for alternative ligands, e.g. compounds that could be generated via a modular approach, in order to study different protein aggregates and their morphologies. Moreover, the use of nuclear imaging techniques, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) for the *in vivo* detection of protein aggregates (such as A $\beta$  aggregates in AD) has increased interest in the development of radiolabelled binding ligands.<sup>18</sup> For example, Pittsburgh compound B, [<sup>11</sup>C]PIB, and Amyvid™ (florbetapir) (Fig. 1) are widely used *in vivo* as indicators for A $\beta$ -deposits in brain tissue.<sup>19–21</sup>

In our search for small molecular scaffolds that bind to protein aggregates, we are particularly interested in synthetic pathways that involve a modular approach (e.g. click chemistry) that could generate diverse derivatives with specific binding properties. Initially for this study, we investigated if the combination of a

<sup>a</sup> Department of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada

<sup>b</sup> Department of Physics, Chemistry and Biology, Linköping University, 581 83 Linköping, Sweden

<sup>c</sup> Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil

<sup>d</sup> CAPES Foundation, Ministry of Education of Brazil, 70040-020 Brasília, DF, Brazil

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c6nj01703g

‡ Division of Organic Chemistry, Department of Physics, Chemistry and Biology, Linköping University, SE-58183, Linköping, Sweden. E-mail: christine.dyrager@liu.se; Tel: +46 13281311.






Fig. 1 Chemical structures of known amyloid- $\beta$  ligands; thioflavin T (ThT), Congo red (CR), Pittsburgh compound B ( $[^{11}\text{C}]\text{PIB}$ ) and Amyvid<sup>TM</sup> (florbetapir).





Fig. 2 Chemical structures of the benzothiazole-triazole (**L1**) and the benzothiadiazole-triazole derivatives (**L2** and **L3**).




1,2,3-triazole moiety and two well-known chromophores, benzothiazole and benzothiadiazole, could afford ligands that exhibit amyloid binding properties in histology samples. Our approach was to use a small azide (3-azidopropan-1-ol) when forming the triazole ring in order to generate model compounds that could be used as a proof-of-concept for amyloid detection.<sup>22,23</sup> Hence, in this paper we report the synthesis and evaluation of three new compounds (one benzothiazole-triazole, **L1**, and two benzothiadiazole-triazoles, **L2** and **L3**, Fig. 2) as potential ligand scaffolds for amyloid- $\beta$  aggregates in mouse brain sections.

## 2. Results and discussion

### 2.1. Synthesis

The target compounds (**L1–L3**) were synthesized as presented in Schemes 1 and 2. The benzothiazole-triazole derivative (**L1**, Scheme 1) was prepared by using commercially available 2-amino-6-methoxy-benzothiazole (**1**) as starting material. First, the amino functionality in the 2-position of **1** was replaced with iodine *via* diazotization-Sandmeyer iodination using KI, NaNO<sub>2</sub> and *p*-toluenesulfonic acid monohydrate in H<sub>2</sub>O/acetonitrile to afford compound **2**.<sup>24</sup> Subsequently, TMS-acetylene was introduced in the 2-position of the iodinated compound (**2**) by using a palladium-mediated Sonogashira coupling under inert conditions with ethynyltrimethylsilane, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, and



**Scheme 2** Synthesis of the benzothiadiazole-triazole derivatives, **L2** and **L3**. *Reagents and conditions:* (a) ethynyltrimethylsilane, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, PPh<sub>3</sub>, CuI, NEt<sub>3</sub>, reflux, 4–18 h; (b) TBAF (1 M in THF), 3-azidopropan-1-ol, CuSO<sub>4</sub>·H<sub>2</sub>O, L-sodium ascorbate, H<sub>2</sub>O, THF, rt, 3 days.

CuI in dichloromethane to give compound **3**. Finally, deprotection of the TMS-group and the subsequent azide-alkyne Huisgen cycloaddition reaction (click chemistry) was performed simultaneously by mixing compound **3** with TBAF (1 M in THF), 3-azidopropan-1-ol, CuSO<sub>4</sub>·H<sub>2</sub>O and L-sodium ascorbate in H<sub>2</sub>O/THF to give compound **L1** in 55% yield.<sup>25,26</sup>



The benzothiadiazole-triazole derivatives (**L2** and **L3**) (Scheme 2) were synthesized using the same procedure as above. However, the syntheses were regulated using different equivalents of the reagents in order to generate the mono- or disubstituted products. First, the starting materials, 4-bromo-2,1,3-benzothiadiazole (**4**) and 4,7-dibromo-2,1,3-benzothiadiazole (**5**), were synthesized using previous reported protocols (ESI,† Scheme S1).<sup>27–29</sup> Subsequently, TMS-acetylene was introduced by a palladium-mediated Sonogashira reaction in the presence of ethynyltrimethylsilane, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, PPh<sub>3</sub> and CuI, in triethylamine. Notably, the crude products were immediately carried forward in the next reaction step

due to limited compound stability. Next, deprotection of the TMS-group and subsequent click reaction was performed simultaneously by mixing the crude product from the previous reaction step with TBAF (1 M in THF), 3-azidopropan-1-ol, CuSO<sub>4</sub>·H<sub>2</sub>O and L-sodium ascorbate in H<sub>2</sub>O/THF, affording **L2** and **L3** in 30% and 69% yield, respectively (over three steps).<sup>30</sup>

## 2.2. Photophysical measurements


### 2.2.1. Photophysical characterization of compound **L1–L3**.

Absorption and emission profiles for **L1–L3** were determined in 5% DMSO in phosphate buffered saline (PBS, 10 mM phosphate, 140 mM NaCl, 2.7 mM KCl, pH 7.4) (Table 1) (for spectra see ESI,† Fig. S1). The molar extinction coefficients for the ligands were similar, ranging from 8000–11 000 [M<sup>−1</sup> cm<sup>−1</sup>]. The benzothiadiazole-triazole derivative (**L1**) showed a high-energy absorption band at 313 nm and emission maxima at 391 nm, whereas the absorption and emission maxima for the benzothiadiazole-triazole derivatives (**L2–L3**) were more redshifted (**L2**:  $\lambda_{\text{abs}} = 353$  nm,  $\lambda_{\text{em}} = 494$  nm; **L3**:  $\lambda_{\text{abs}} = 387$  nm,  $\lambda_{\text{em}} = 531$  nm). These results were expected since the benzothiadiazole fragment is well known for its interesting photophysical properties, such as the strong electron-withdrawing capacity that facilitates intramolecular charge transfer (ICT), large

**Table 1** Spectroscopic data for compounds **L1–L3** measured in 5% DMSO in phosphate buffered saline (PBS, 10 mM phosphate, 140 mM NaCl, 2.7 mM KCl, pH 7.4)

Compound	$\lambda_{\text{abs}}$ (nm)	$\lambda_{\text{em}}$ (nm)	Stoke's shift (nm)	$\epsilon$ [M <sup>−1</sup> cm <sup>−1</sup> ]	$\phi_F^a$
<b>L1</b>	313	391	78	9000	0.67
<b>L2</b>	353	494	141	11 000	0.24
<b>L3</b>	387	531	144	8000	0.31

<sup>a</sup> Determined relative to quinine sulfate in aqueous H<sub>2</sub>SO<sub>4</sub> (0.1 M).



**Fig. 3** Excitation (left) and emission (right) spectra of **L1** (a), **L2** (b), and **L3** (c) in the presence (red line) or absence (black line) of recombinant A $\beta_{1-42}$  fibrils in 5% DMSO in phosphate buffered saline (PBS, 10 mM phosphate, 140 mM NaCl, 2.7 mM KCl, pH 7.4). The reduced emission intensities are represented by the light grey striped area. The measurements were performed in a 5:1 ratio, ligand to fibrils, using the concentrations 50  $\mu$ M and 10  $\mu$ M, respectively.




Stoke's shifts, high signal-to-noise ratio in cells and red-shifted optical profiles.<sup>31</sup> In particular, the latter is beneficial in protein binding studies and tissue staining experiments due to the use of lower energies for excitation, and resulting lower autofluorescence signals and reduced light scattering. Further, quantum yield measurements for the ligands (in 5% DMSO in PBS buffer, pH 7.4) afforded moderate to high  $\phi_F$  values (0.67, 0.24 and 0.31 for **L1**, **L2** and **L3**, respectively) (Table 1). The pH dependence (pH 2–12) of the fluorophores was also investigated, and the fluorescent intensities and emission maxima was unchanged in a wide range (pH 4–12, see ESI,† Fig. S2). However, a reduced intensity was observed at pH 2, likely due to protonation of the benzothia(dia)zole fragments.<sup>32</sup> Despite the blue-shifted absorption and emission maxima for **L1** we further investigate all three compounds (**L1**–**L3**) for their amyloid binding potential in solution and in AD brain tissue.

**2.2.2. Photophysical characterization of the benzothiazole-triazole (**L1**) and benzothiadiazole-triazole derivatives (**L2** and **L3**) towards recombinant A $\beta_{1-42}$  amyloid fibrils.** In order to evaluate potential interactions with protein aggregates, excitation and emission spectra of the ligands (**L1**–**L3**) were recorded in the absence and the presence of amyloid-like fibrils, generated from recombinant A $\beta_{1-42}$  (Fig. 3). Initially, the emission spectra of **L1**–**L3** in the presence of 10  $\mu$ M A $\beta$ -fibrils were collected using different concentrations of the ligands (0.3, 0.6, 0.9, 1.2, 10 and

100  $\mu$ M) (spectra not shown). However, a ligand concentration of 50  $\mu$ M was chosen for further analysis due to the optimal linear-response between absorbance and integrated fluorescence intensity (ESI,† Fig. S4). Interestingly, all three ligands show reduced fluorescence (intensity area), approx. 20% (reduced excitation intensity: **L1** = 16%, **L2** = 17%, **L3** = 23%; reduced emission intensity: **L1** = 17%, **L2** = 21%, **L3** = 17%), when mixed with the fibrils in solution, quite the contrary to ThT, which shows an increase in emission intensity. Interestingly, the absorbance-integrated luminescence intensity curves for **L1**–**L3** (ESI,† Fig. S4) show fluorescence quenching (**L3** > **L1** > **L2**) at high concentrations (>100  $\mu$ M) in the absence of aggregates, and we thus hypothesize that the decreased intensity in the fibril experiment could originate from proximity-induced self-quenching of the ligands upon interaction with the A $\beta$ -fibrils.<sup>33–37</sup> Even if the ligands have a different photo-physical behavior in comparison to ThT, the approx. 20% reduced intensity provides a useful and pronounced evidence of ligand–fibril interaction without approaching the limit of detection.

### 2.3. Staining of A $\beta$ -plaques in brain tissue sections from transgenic mice

A $\beta$  plaques in the APP/PS1 mouse model of AD pathology<sup>38</sup> were stained simultaneously with the ligands **L1**, **L2** or **L3** and with an anti-A $\beta$  antibody (6E10) and then imaged *via* channels selective for



**Fig. 4** Fluorescence microscopy images of A $\beta$  deposits in brain sections from APP/PS1 mice stained with **L1** (a) **L2** (b) and **L3** (c), and with an anti-A $\beta$  antibody (6E10). White arrows point towards the localization of three representative amyloid deposits in each image stained with ligand (panels to the left) or anti-A $\beta$  antibody (6E10) (panels in the middle). Panels to the right show both channels in order to clarify the co-localization between ligand (seen in blue) and the anti-A $\beta$  antibody (seen in red). The emission spectra (excitation at 405 nm) of each ligand binding to the core of three different A $\beta$  plaques (labeled as region 1, 2 and 3) are shown to the far right. The scale bar in the lower right corner of each image represents 50  $\mu$ m.





one or the other stain (excitation at 405 and 680 nm, respectively). The resulting images (Fig. 4) clearly demonstrate that all three ligands bind to A $\beta$  plaques with specificity and accuracy with **L3** affording the best signal to background contrast. All three ligands display preferential binding to the plaque cores analogous to what has been described previously for this mouse model when stained with ThT or CN-PIB, which is expected due to the overall similarity in chemical structure between the ligands (**L1**–**L3**) and the well-established counterparts.<sup>39</sup> This in turn holds promise that these new ligands may play a significant role as scaffolds for further development of amyloid-binding ligands with specific designs for various purposes using click chemistry for rapid multipurpose modification to improve binding affinities and pharmacokinetics.

Notably, as depicted in Fig. 4a (to the far right), the emission profile for **L1** is more redshifted ( $\lambda_{\text{em}} \sim 470$  nm) in the fluorescent microscopy experiment (using histology samples) in comparison with the photophysical characterization measurements in 5% DMSO in PBS buffer ( $\lambda_{\text{em}} = 394$  nm) (Table 1). We hypothesized that this result was not an optical effect that originates from binding to the A $\beta$  deposits in brain tissue, and instead a result from using a longer excitation wavelength (*i.e.* 405 nm instead of 310 nm) in the tissue experiment. Furthermore, the redshift was verified by measuring the emission spectra of **L1** in 5% DMSO in phosphate buffered saline (PBS, 10 mM phosphate, 140 mM NaCl, 2.7 mM KCl, pH 7.4) when exciting at 405 nm, which afforded an emission maxima at 472 nm (see ESI,† Fig. S5a). However, even though it is possible to excite **L1** at a lower energy and generate a red-shifted emission profile, we clearly observed that the benzothiadiazole derivatives **L2** and **L3** are much brighter, affording higher signal-to-noise ratios in the fluorescent microscopy experiments using brain tissue sections. These derivatives are therefore superior ligands for further development.

### 3. Conclusions

We have shown that the benzothiazole-triazole and the benzothiadiazole-triazole scaffolds constitute new promising classes of ligands for amyloid- $\beta$  detection. The ligands show a significant reduction of the emission (approx. 20%) in the presence of recombinant A $\beta_{1-42}$  amyloid fibrils in solution, an effect that likely originates from self-quenching of the ligands upon interaction with the protein fibrils. Histology staining of A $\beta$ -plaques in mouse brain sections demonstrates specific binding to amyloid deposits for all three ligands, which were verified by co-labeling with an anti-A $\beta$  antibody (6E10). Even though the present ligands are not superior in comparison to ThT for sensitive fluorescence detection of protein aggregates, we foresee that the synthetic pathway (azide-alkyne cycloaddition) described herein, will offer an avenue to design a variety of structurally diverse ligands that exhibit specific binding to different protein aggregates. Suggestively, the approach also enables the introduction of substituents that includes radioactive isotopes (*e.g.* [<sup>18</sup>F]) for PET or SPECT imaging. Our intention is to further investigate a library of benzothiadiazole ligands, formed *via* click

chemistry, to generate amyloid binding agents and that can distinguish between different protein aggregates in solution and in amyloid containing brain tissue.

## 4. Experimental

### 4.1. Chemistry

All reagents and solvents were of analysis or synthesis grade and were used without further purification unless otherwise indicated. <sup>1</sup>H and <sup>13</sup>C NMR were recorded on a Bruker AVANCE III 400 MHz NMR (at 400 and 100 MHz, respectively) or on a Varian 300 instrument (Varian Inc., Santa Clara, CA, USA) (at 300 and 75 MHz, respectively) in CDCl<sub>3</sub> or DMSO-*d*<sub>6</sub>. Chemical shift is reported in ppm with the solvent residual peak as reference; CDCl<sub>3</sub> ( $\delta_{\text{H}}$  7.26,  $\delta_{\text{C}}$  77.0), DMSO-*d*<sub>6</sub> ( $\delta_{\text{H}}$  2.50,  $\delta_{\text{C}}$  39.5) and CD<sub>3</sub>OD ( $\delta_{\text{H}}$  4.87,  $\delta_{\text{C}}$  49.0). The reactions were monitored by thin-layer chromatography (TLC), on silica plated (Silica gel 60 F<sub>254</sub>, E. Merck) aluminium sheets, detecting spots by UV (254 and 365 nm). Flash chromatography was performed using Merck Silica Gel 60 (40–63  $\mu$ m). Mass spectra were obtained with the positive ion mode electrospray ionization [ESI(+)] source on an Agilent 6210 time of-flight liquid chromatography/mass spectrometry (MS) system. High-resolution mass data (ES-ToF) were obtained from the Division of Mass spectrometry, Department of Chemistry, Imperial College London.

**4.1.1. 2-Iodo-5-methoxybenzo[d]thiazole (2)**<sup>24</sup>. The reaction was carried out under nitrogen atmosphere in order to have an evacuation line for the N<sub>2</sub> gas that is formed during the reaction. A solution of NaNO<sub>2</sub> (0.153 g, 2.22 mmol) and KI (0.461 g, 2.77 mmol) in H<sub>2</sub>O (0.7 mL) was added dropwise to an ice-cooled suspension of 2-amino-6-methoxy-benzothiazole (**1**) (0.2 g, 1.11 mmol) and *p*-toluenesulfonic acid monohydrate (0.633 g, 3.33 mmol) in acetonitrile (5.5 mL). The reaction was allowed to reach room temperature and was stirred overnight. The reaction mixture was quenched with H<sub>2</sub>O (20 mL), basified with 2 M NaHCO<sub>3</sub>(aq.) until pH reached 8–9, follow by the addition of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>(aq.) (2.5 mL) to give a yellow/brown precipitate. The precipitate was filtered off and dried *in vacuo* to give compound **2** as a brown/gold power (0.245 g, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.86 (s, 3H), 7.03 (dd, *J* = 2.6, 9.0 Hz, 1H), 7.28 (d, *J* = 2.6 Hz, 1H), 7.90 (d, *J* = 9.0 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  55.8, 101.5, 103.0, 115.6, 123.0, 149.4, 149.0, 158.0. ESI(+)-MS (*m/z*): [M + H]<sup>+</sup> calcd for C<sub>8</sub>H<sub>7</sub>INOS, 291.9288. Found, 291.9318.

**4.1.2. 6-Methoxy-2-((trimethylsilyl)ethynyl)benzo[d]thiazole (3)**<sup>25,26</sup>. The reaction was carried out under inert conditions (N<sub>2</sub>). Ethynyltrimethylsilane (0.49 mL, 3.44 mmol) was added to a suspension of compound **2** (0.5 g, 1.72 mmol), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (0.024 g, 0.03 mmol), and CuI (6.5 mg, 0.03 mmol) in dry dichloromethane (2.5 mL). The reaction was refluxed for 3 hours and was then allowed to reach room temperature. The mixture was filtered through a layer of Celite and concentrated under reduced pressure. The crude product was purified by column chromatography (10% EtOAc in hexanes) to give compound **3** as a light yellow powder (0.312 g, 69%). The product was used in



the next reaction step immediately or stored in the freezer for a limited time due to stability issues.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  0.30 (s, 9H), 3.88 (s, 3H), 7.11 (dd,  $J$  = 2.5, 9.1 Hz, 1H), 7.28 (d,  $J$  = 2.5 Hz, 1H), 7.92 (d,  $J$  = 9.0 Hz, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  0.5, 55.8, 96.9, 102.2, 103.3, 116.5, 124.2, 136.7, 145.6, 147.2, 158.8. ESI(+)-MS  $m/z$ :  $[\text{M} + \text{H}]^+$  calcd for  $\text{C}_{13}\text{H}_{16}\text{NOSSi}$ , 262.0716. Found 262.0738.

**4.1.3. 3-(4-(5-Methoxybenzo[d]thiazol-2-yl)-1H-1,2,3-triazol-1-yl)propan-1-ol (L1)**<sup>25,26</sup>. TBAF (1 M in THF, 4.56 mL) was added dropwise to a stirred solution of **3** (0.298 g, 1.14 mmol) in THF (10 mL). Subsequently, 3-azidopropan-1-ol (0.231 g, 2.28 mmol) was added and then a solution of  $\text{CuSO}_4 \cdot \text{H}_2\text{O}$  (0.114 g, 0.456 mmol) and L-sodium ascorbate (0.090 g, 0.456 mmol) in  $\text{H}_2\text{O}$  (10 mL). The reaction mixture was stirred at room temperature for 3 days and then Chelex resin (approx. a small spoon) was added to remove the Cu catalyst. The solution was filtered after 30 min, to remove the Chelex resin, and was then concentrated under reduced pressure. The crude residue was purified by column chromatography (100% EtOAc) to give the product (**L1**) as an off white powder (0.182 g, 55%).  $M_p$  161–162 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  2.00–2.09 (m, 2H), 3.44 (dd,  $J$  = 6.0, 11.1 Hz, 2H), 3.85 (s, 3H), 4.53 (t,  $J$  = 7.1 Hz, 2H), 4.71 (t,  $J$  = 5.0 Hz, 1H), 7.13 (dd,  $J$  = 2.5, 8.9 Hz, 1H), 7.73 (d,  $J$  = 2.5 Hz, 1H), 7.90 (d,  $J$  = 8.9 Hz, 1H), 8.85 (s, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO}-d_6$ )  $\delta$  32.6, 47.3, 55.7, 57.4, 104.9, 115.9, 123.1, 223.4, 135.3, 141.9, 147.6, 156.5, 157.5. HRMS (ES-ToF)  $[\text{M} + \text{H}]^+$  calcd for  $\text{C}_{13}\text{H}_{15}\text{N}_4\text{O}_2\text{S}$ , 291.0916. Found, 291.0924.

**4.1.4. 3-(4-(Benzo[c][1,2,5]thiadiazol-4-yl)-1H-1,2,3-triazol-1-yl)propan-1-ol (L2)**<sup>30</sup>. The reaction was performed under inert conditions ( $\text{N}_2$ ). Ethynyltrimethylsilane (0.28 mL, 1.95 mmol) was added to a stirred solution of **4** (0.3 g, 1.39 mmol),  $\text{PPh}_3$  (0.038 g, 0.14 mmol), CuI (0.037 g, 0.195 mmol) and  $\text{PdCl}_2(\text{PPh}_3)_2$  (6.0 mg, 0.008 mmol) in  $\text{NEt}_3$  (3 mL). The mixture was heated at 90 °C for 18 hours and was then allowed to reach room temperature. The reaction mixture was diluted with dichloromethane (10 mL) and was then quickly filtered through a small silica column. The filtrate was concentrated under reduced pressure to give a crude solid that was used immediately in the next reaction step due to stability issues. TBAF (1 M in THF, 2.79 mL) was added dropwise to a stirred solution of the crude material in THF (10 mL). Subsequently, 3-azidopropan-1-ol (0.282 g, 2.79 mmol) was added followed by the addition of a solution of  $\text{CuSO}_4 \cdot \text{H}_2\text{O}$  (0.139 g, 0.56 mmol) and L-sodium ascorbate (0.111 g, 0.56 mmol) in  $\text{H}_2\text{O}$  (10 mL). The reaction mixture was stirred at room temperature for 3 days and then Chelex resin (approx. a small spoon) was added to remove the Cu catalyst. The solution was stirred for 30 min and was then filtered in order to remove the Chelex resin. The filtrate was concentrated under reduced pressure and the crude residue was purified by column chromatography (100% EtOAc) to give **L2** as yellow powder (0.110 g, 30%).  $M_p$  114–115 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  2.21 (ddd,  $J$  = 6.1, 7.0, 13.1 Hz, 2H), 3.65 (t,  $J$  = 6.1 Hz, 2H), 4.66 (t,  $J$  = 7.0 Hz, 2H), 7.76 (dd,  $J$  = 7.1, 8.8 Hz, 1H), 8.00 (dd,  $J$  = 1.0, 8.8 Hz, 1H), 8.38 (dd,  $J$  = 1.0, 7.1 Hz, 1H), 8.89 (s, 1H). The OH-signal was not observed in the spectrum, due to solvent exchange.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  34.1,

48.5, 59.3, 121.9, 124.6, 126.2, 126.3, 131.0, 143.9, 153.0, 156.6. HRMS (ES-ToF)  $[\text{M} + \text{H}]^+$  calcd for  $\text{C}_{11}\text{H}_{12}\text{N}_5\text{OS}$ , 262.0763. Found, 262.0772.

**4.1.5. 3,3'-(Benzo[c][1,2,5]thiadiazole-4,7-diylbis(1H-1,2,3-triazole-4,1-diyl))bis(propan-1-ol) (L3)**<sup>30</sup>. The reaction was performed under inert conditions ( $\text{N}_2$ ). Ethynyltrimethylsilane (0.4 mL, 2.86 mmol) was added to a stirred solution of **5** (0.3 g, 1.02 mmol),  $\text{PPh}_3$  (0.027 g, 0.1 mmol), CuI (0.027 g, 0.143 mmol) and  $\text{PdCl}_2(\text{PPh}_3)_2$  (4.3 mg, 0.006 mmol) in  $\text{NEt}_3$  (5 mL). The mixture was heated at 90 °C for 4 hours and was then allowed to reach room temperature. The reaction mixture was diluted with dichloromethane (10 mL) and was then quickly filtered through a small silica column. The filtrate was concentrated under reduced pressure to give a crude solid that was used immediately in the next reaction step due to stability issues. TBAF (1 M in THF, 4.08 mL) was added dropwise to a stirred solution of the crude material in THF (10 mL). Subsequently, 3-azidopropan-1-ol (0.248 g, 2.45 mmol) was added followed by the addition of a solution of  $\text{CuSO}_4 \cdot \text{H}_2\text{O}$  (0.051 g, 0.20 mmol) and L-sodium ascorbate (0.040 g, 0.2 mmol) in  $\text{H}_2\text{O}$  (10 mL). The reaction mixture was stirred at room temperature for 3 days and then Chelex resin (approx. a small spoon) was added to remove the Cu catalyst. The solution was stirred for 30 min and was then filtered in order to remove the Chelex resin. The filtrate was concentrated under reduced pressure and the crude residue was purified by column chromatography (100% EtOAc  $\rightarrow$  10% EtOH in EtOAc) to give the **L3** as yellow powder (0.274 g, 69%).  $M_p$  170–171 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  2.18 (m, 4H), 3.66 (t,  $J$  = 6.1 Hz, 4H), 4.67 (t,  $J$  = 7.0 Hz, 4H), 8.49 (s, 2H), 9.01 (s, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO}-d_6$ )  $\delta$  33.0, 46.9, 57.4, 122.3, 124.7, 125.3, 141.7, 151.5. HRMS (ES-ToF)  $[\text{M} + \text{H}]^+$  calcd for  $\text{C}_{16}\text{H}_{19}\text{N}_8\text{O}_2\text{S}$ , 387.1352. Found, 387.1338.

## 4.2. Photophysical measurements

**4.2.1. Photophysical characterization of compounds L1–L3.** All photophysical measurements were performed in 5% DMSO in 0.1 M PBS buffer (pH 7.4) using 1 cm path length quartz cuvettes. Absorption spectra were collected using a Varian CARY 5000 UV-visible-near IR spectrophotometer or a Hitachi U-1900 spectrophotometer. The emission data were collected using a Photon Technology International 814 photomultiplier detection system or a Horiba Jobin-Yvon Fluoromax-4 instrument, and the signals were collected at 90° to the incident excitation beam. The final concentrations of ligands were approximately 100  $\mu\text{M}$  and 100 nM for the absorption and emission measurements, respectively (ESI,† Fig. S1). Extinction coefficients were determined from samples of known concentrations. Quantum yields (QY) were measured relative to quinine sulfate (QY = 0.577)<sup>40</sup> in aqueous  $\text{H}_2\text{SO}_4$  (0.1 M). The refraction index for the solvent mixture (5% DMSO/ $\text{H}_2\text{O}$ ) was included in the calculations ( $n$  = 1.3390).<sup>41</sup> The concentration-absorbance relationship and the absorbance-integrated fluorescence intensity relationship were measured at known concentrations (20, 40, 60, 80, 100 and 250  $\mu\text{M}$ ) using a Tecan Sapphire 2 micro plate reader (Tecan Group Ltd, Männedorf, Switzerland). All the measurements were repeated in triplicates with an excitation wavelength of 310, 350 and 370 nm for **L1**, **L2** and **L3**, respectively.



**4.2.2. Photophysical characterization of the benzothiazole-triazole (L1) and benzothiadiazole-triazole derivatives (L2 and L3) towards recombinant A $\beta$ <sub>1-42</sub> amyloid fibrils.** Recombinant A $\beta$ <sub>1-42</sub> amyloid fibrils were prepared as previously reported in the literature; recombinant A $\beta$ <sub>1-42</sub> peptide lyophilized in hydroxyfluoroisopropanol (rPeptide, Athens, GA, USA) was dissolved in aqueous NaOH (2 mM) to a stock concentration of 1 mg mL<sup>-1</sup>. The alkaline solution of A $\beta$ <sub>1-42</sub> was further diluted with phosphate buffered saline (PBS, 10 mM phosphate, 140 mM NaCl, 2.7 mM KCl, pH 7.4) (Medicago, Sweden) to a final concentration of 10  $\mu$ M and added to the wells of a microtiter plate (Corning). The microtiter plate was incubated at 37 °C in quiescent mode for 48 hours and the presence of recombinant A $\beta$ <sub>1-42</sub> amyloid fibrils was confirmed by thioflavin T (ThT) staining. Stock solutions of **L1**, **L2** and **L3** (1 mM in DMSO) was added to phosphate buffered saline (PBS, 10 mM phosphate, 140 mM NaCl, 2.7 mM KCl, pH 7.4) or to the 10  $\mu$ M solution of A $\beta$ <sub>1-42</sub> fibrils in phosphate buffered saline (PBS, 10 mM phosphate, 140 mM NaCl, 2.7 mM KCl, pH 7.4), respectively, in a 96-well plate to give a final probe concentration of 50  $\mu$ M (5% DMSO in phosphate buffered saline, PBS, 10 mM phosphate, 140 mM NaCl, 2.7 mM KCl, pH 7.4). Emission spectra were collected using a Tecan Sapphire 2 micro plate reader (Tecan Group Ltd, Männerdorf, Switzerland). All measurements were repeated in triplicates and the excitation wavelengths used for **L1**, **L2** and **L3** were 310, 365 and 400 nm, respectively.

#### 4.3. Staining of A $\beta$ plaques in mouse brain sections

This study did not directly involve experiments or handling of live animals. The brain tissue sections with AD pathology were provided by Prof. Frank Heppner, Department of Neuropathology, Charité – Universitätsmedizin Berlin, Germany. Animal handling to provide the histology samples used herein was carried out in accordance with relevant ethical guidelines of breeding and keeping transgenic animals as well as culling and collection of tissue for *ex vivo* experiments (approved by the Swiss cantonary veterinary office or the regional offices for health and social services in Berlin). 10  $\mu$ m cryosections of a 531 days old APP/PS1 mouse<sup>38</sup> were placed on superfrost ultraplus glass slides. The sections were fixed in 99% ethanol for 10 minutes and rehydrated with increasing proportion of dH<sub>2</sub>O followed by equilibration in PBS pH 7.4 (Medicago, Sweden) for 10 minutes. Monoclonal anti-A $\beta$  antibody 6E10 was diluted 1:200 in PBS, administered to the sections and left at 4 °C overnight followed by extensive washing with PBS. Goat-antimouse secondary antibody with fluorescence detection maximum at 647 nm (GAM650, Dako, Denmark) was diluted 1:500 and incubated on the sections for 30 minutes followed by washing with PBS. The ligands were diluted from 5 mM stocks in DMSO to 10  $\mu$ M working solution in PBS immediately prior to use. The ligand working solutions were applied to the sections and left at room temperature for 30 minutes followed by destaining by dipping in PBS for 10 minutes. The glass slides were left to dry in ambient air and finally mounted with Dako fluorescence mounting medium and a cover slip. Images were collected using an inverted Zeiss LSM 780 confocal microscope (Carl Zeiss, Oberkochen, Germany)

with excitation wavelength at 405 nm (**L1–L3**) and 680 nm (anti-A $\beta$  antibody 6E10).

## Acknowledgements

This work was supported by an International postdoctoral grant from the Swedish Research Council, Dnr: 350-2012-239 (to C. D.), The Swedish Alzheimer's Foundation (to S. N.), Ciência sem Fronteiras (Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil, Proc. No. 245405/2012-7) and Fundação CAPES (Bolsista CAPES, Projeto PVE 118/2013) (to R. P. V.), and a Michael Smith Foundation for Health Research career Investigator Award (to T. S.). The authors also thank Alexander Sandberg and Leif B. G. Johansson for providing the amyloid-like fibrils, generated from recombinant A $\beta$ <sub>1-42</sub>. The brain tissue sections with AD like pathology was provided by Prof. Frank Heppner, Department of Neuropathology, Charité – Universitätsmedizin Berlin, Germany.

## Notes and references

- 1 D. J. Selkoe, *Physiol. Rev.*, 2001, **81**, 741.
- 2 V. H. Finder, *J. Alzheimer's Dis.*, 2010, **22**, 5.
- 3 K. J. Barnham, C. L. Masters and A. I. Bush, *Nat. Rev. Drug Discovery*, 2004, **3**, 205.
- 4 A. S. DeToma, S. Salamekh, A. Ramamoorthy and M. H. Lim, *Chem. Soc. Rev.*, 2012, **41**, 608.
- 5 M. Xu, W. Ren, X. Tang, Y.-H. Hu and H. Zhang, *Acta Pharmacol. Sin.*, 2016, **37**, 719.
- 6 M. Shimojo, M. Higuchi, T. Suhara and N. Sahara, *Front. Neurosci.*, 2015, **9**, 482.
- 7 K. P. Nilsson, *FEBS Lett.*, 2009, **583**, 2593.
- 8 P. A. Adlard, B. A. Tran, D. I. Finkelstein, P. M. Desmond, L. A. Johnston, A. I. Bush and G. F. Egan, *Front. Neurosci.*, 2014, **8**, 327.
- 9 H. Naiki, K. Higuchi, M. Hosokawa and T. Takeda, *Anal. Biochem.*, 1989, **177**, 244.
- 10 H. LeVine, 3rd, *Protein Sci.*, 1993, **2**, 404.
- 11 E. S. Voropai, M. P. Samtsov, K. N. Kaplevskii, A. A. Maskevich, V. I. Stepuro, O. I. Povarova, I. M. Kuznetsova, K. K. Turoverov, A. L. Fink and V. N. Uverskii, *J. Appl. Spectrosc.*, 2003, **70**, 868.
- 12 A. A. Reinke, G. A. Abulwerdi and J. E. Gestwicki, *ChemBioChem*, 2010, **11**, 1889.
- 13 M. R. Nilsson, *Methods*, 2004, **34**, 151.
- 14 H. Bennhold, *Muench. Med. Wochenschr.*, 1922, **69**, 1537.
- 15 P. Divry, *J. Neurol. Psychiatry*, 1927, **27**, 643.
- 16 P. Frid, S. V. Anisimov and N. Popovic, *Brain Res. Rev.*, 2007, **53**, 135.
- 17 G. T. Westermark, K. H. Johnson and P. Westermark, *Methods Enzymol.*, 1999, **309**, 3.
- 18 L. Zhu, K. Ploessl and H. F. Kung, *Chem. Soc. Rev.*, 2014, **43**, 6683.
- 19 W. E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, D. P. Holt, M. Bergström, I. Savitcheva, G.-F. Huang, S. Estrada, B. Ausén, M. L. Debnath, J. Barletta, J. C. Price,



- J. Sandell, B. J. Lopresti, A. Wall, P. Koivisto, G. Antoni, C. A. Mathis and B. Långström, *Ann. Neurol.*, 2004, **55**, 306.
- 20 C. M. Clark, J. A. Schneider, B. J. Bedell, T. G. Beach, W. B. Bilker, M. A. Mintun, M. J. Pontecorvo, F. Hefti, A. P. Carpenter, M. L. Flitter, M. J. Krautkramer, H. F. Kung, R. E. Coleman, P. M. Doraiswamy, A. S. Fleisher, M. N. Sabbagh, C. H. Sadowsky, E. P. Reiman, S. P. Zehntner and D. M. Skovronsky, *JAMA*, 2011, **305**, 275.
- 21 S. R. Choi, J. A. Schneider, D. A. Bennett, T. G. Beach, B. J. Bedell, S. P. Zehntner, M. J. Krautkramer, H. F. Kung, D. M. Skovronsky, F. Hefti and C. M. Clark, *Alzheimer Dis. Assoc. Disord.*, 2012, **26**, 8.
- 22 M. R. Jones, E. L. Service, J. R. Thompson, M. C. P. Wang, I. J. Kimsey, A. S. DeToma, A. Ramamoorthy, M. H. Lim and T. Storr, *Metallomics*, 2012, **4**, 910.
- 23 M. R. Jones, C. Dyrager, M. Hoarau, K. J. Korshavn, M. H. Lim, A. Ramamoorthy and T. Storr, *J. Inorg. Biochem.*, 2016, **158**, 131.
- 24 E. A. Krasnokutskaya, N. I. Semenischeva, V. D. Filimonov and P. Knochel, *Synthesis*, 2007, 81.
- 25 J. Qi, M. S. Han, Y. C. Chang and C. H. Tung, *Bioconjugate Chem.*, 2011, **22**, 1758.
- 26 J. Qi and C. H. Tung, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 320.
- 27 B. Wang, S. W. Tsang, W. Zhang, Y. Tao and M. S. Wong, *Chem. Commun.*, 2011, **47**, 9471.
- 28 B. A. Coombs, B. D. Lindner, R. M. Edkins, F. Rominger, A. Beeby, H. Uwe and F. Bunz, *New J. Chem.*, 2012, **36**, 550.
- 29 R. C. Lirag, H. T. Le and O. S. Miljanic, *Chem. Commun.*, 2013, **49**, 4304.
- 30 A. V. Moro, P. C. Ferreira, P. Migowski, F. S. Rodembusch, J. Dupont and D. S. Ludtke, *Tetrahedron*, 2013, **69**, 201.
- 31 B. A. Neto, P. H. Carvalho and J. R. Correa, *Acc. Chem. Res.*, 2015, **48**, 1560.
- 32 A. K. Sharma, S. T. Pavlova, J. Kim, D. Finkelstein, N. J. Hawco, N. P. Rath, J. Kim and L. M. Mirica, *J. Am. Chem. Soc.*, 2012, **134**, 6625.
- 33 X. Zhuang, T. Ha, H. D. Kim, T. Centner, S. Labeit and S. Chu, *Proc. Natl. Acad. Sci. U. S. A.*, 2000, **97**, 14241.
- 34 D. C. Harris, *Quantitative Chemical Analysis*, W. H. Freeman, 2010.
- 35 J. R. Lakowicz, *Principles of Fluorescence Spectroscopy*. Springer, US, 2007.
- 36 S. M. Auerbach, K. A. Carrado and P. K. Dutta, *Handbook of Layered Materials*, CRC Press, 2004.
- 37 J. Zhang, Y. Fu and J. R. Lakowicz, *J. Phys. Chem. C*, 2007, **111**, 1955.
- 38 R. Radde, T. Bolmont, S. A. Kaeser, J. Coomaraswamy, D. Lindau, L. Stoltze, M. E. Calhoun, F. Jaggi, H. Wolburg, S. Gengler, C. Haass, B. Ghetti, C. Czech, C. Holscher, P. M. Mathews and M. Jucker, *EMBO Rep.*, 2006, **7**, 940.
- 39 S. Nystrom, K. M. Psonka-Antonczyk, P. G. Ellingsen, L. B. Johansson, N. Reitan, S. Handrick, S. Prokop, F. L. Heppner, B. M. Wegenast-Braun, M. Jucker, M. Lindgren, B. T. Stokke, P. Hammarstrom and K. P. Nilsson, *ACS Chem. Biol.*, 2013, **8**, 1128.
- 40 J. W. Eastman, *Photochem. Photobiol.*, 1967, **6**, 55.
- 41 A. S. L. Gouveia, L. C. Tomé and I. M. Marrucho, *J. Chem. Eng. Data*, 2016, **61**, 83.

